髋臼周围肿瘤切除:巨大同种异体骨-假体复合重建是否仍有作用?
回顾性分析1994年至2023年在单中心接受髋臼周围肿瘤整块切除后行同种异体骨-假体复合重建的49例患者,5年主要并发症累积发生率为24%(95%CI 13%至37%),10年和15年均为33%(95%CI 20%至46%);末次随访MSTS评分为23±5分,15年移植物取出累积发生率为12%(95%CI 4%至24%)。作者认为该重建方式可能仍是有效选择,尤其适用于预期寿命长、未接受化放疗且髂骨翼完全或部分保留的患者,但需更大规模研究比较不同重建方式。
要点
- 5年主要并发症累积发生率为24%(95%CI 13%至37%),10年和15年均为33%(95%CI 20%至46%)。
- 末次随访MSTS评分为23±5分,评估时间为术后10±6年。
- 15年移植物取出累积发生率为12%(95%CI 4%至24%)。
核心结论
- 同种异体骨-假体复合重建可能仍是髋臼周围原发骨肿瘤切除后的有效重建选择,即使在3D打印假体时代。
- 该技术可能对预期寿命长、未接受化疗或放疗且髂骨翼完全或部分保留的患者仍有作用。
- 需要更大规模研究比较髋臼周围同种异体骨-假体复合重建与模块化及定制假体、回收自体骨-假体复合重建等其他重建方式,以评估不同技术的潜在优势。
研究设计与样本
- 回顾性研究,纳入1994年2月至2023年4月在佛罗伦萨大学医院因骨盆原发或继发恶性或侵袭性良性骨肿瘤行整块切除的174例患者中的51例接受髋臼周围切除及同种异体骨-假体复合重建者。
- 纳入标准为随访至少24个月或早期出现并发症,最终96%(49/51)的患者纳入分析;其中88%(43/49)随访至少24个月,12%(6/49)随访不足24个月但早期出现并发症,纳入无并发症生存分析。
- 平均随访时间100±77个月,重建时平均年龄47±17岁,女性37%(18/49),男性63%(31/49)。
- 按Enneking和Dunham骨盆切除分型:I-II型39%(19例),II型24%(12例),II-III型22%(11例),I-II-III型8%(4例),I-II-IV型4%(2例),I-II-III-IV型2%(1例)。
- 重建方式:骨盆同种异体骨联合髋臼笼78%(38例),单纯骨水泥杯16%(8例),带柄非骨水泥杯6%(3例)。
主要发现
- 主要并发症(定义为因机械并发症和/或感染对重建任何组件行手术翻修,无论感染是否手术治疗)5年累积发生率为24%(95%CI 13%至37%),10年和15年均为33%(95%CI 20%至46%)。
- 移植物取出(作为失败终点)5年和10年累积发生率为8%(95%CI 3%至18%),15年为12%(95%CI 4%至24%)。
- 末次随访MSTS评分为23±5分,评估时间为术后10±6年。
- 并发症通过复习临床病历评估,死亡作为竞争事件;功能结果通过机构数据库复习评估。
关键数值与推荐
- 主要并发症累积发生率:5年24%(95%CI 13%至37%),10年和15年均为33%(95%CI 20%至46%)。
- 移植物取出累积发生率:5年和10年均为8%(95%CI 3%至18%),15年为12%(95%CI 4%至24%)。
- MSTS评分:23±5分(评估时间10±6年)。
临床怎么用
- 作者认为同种异体骨-假体复合重建可能仍是髋臼周围原发骨肿瘤切除后的有效重建选择,尤其适用于预期寿命长、未接受化疗或放疗且髂骨翼完全或部分保留的患者。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Allograft-prosthesis composite reconstruction after periacetabular resections allows for bony union and internal repair, restoring bone stock for further revisions; the allograft-prosthesis composite can be shaped according to the pelvic resection to reconstruct the complex bone anatomy. Recently, endoprosthetic reconstruction has become one of the most frequently used options to restore large periacetabular bone defects. However, a prosthetic reconstruction impairs pelvic bone stock preservation and often takes a long time to manufacture. Allograft reconstructions, on the other hand, allow for bony union and internal repair, and they restore bone stock for further revisions. In addition, allografts are usually readily available and can be shaped according to the pelvic resection, fully restoring the complex bone anatomy. Pelvic biological reconstructions may have still a role, and to our knowledge, there are few long-term results of allograft-prosthesis composite reconstruction of the pelvis after periacetabular resections for bone tumors. QUESTIONS/PURPOSES: (1) What is the cumulative incidence percentage of patients who experienced complications after reconstruction with allograft-prosthesis composites after resection of periacetabular tumors? (2) What was the functional result after surgical treatment as assessed by the Musculoskeletal Tumor Society (MSTS) score at a minimum of 2 years? (3) What was the survivorship of these reconstructions free from revision and graft removal at 15 years? METHODS: Between February 1994 and April 2023, a total of 174 patients were treated at the university hospital of Florence for primary and secondary malignant or aggressive benign bone tumors of the pelvis with en bloc resection. Of treated patients, 51 underwent periacetabular resection and allograft-prosthesis composite reconstruction. We included in the study only patients with at least 24 months of follow-up or those who had complications earlier; thus 96% (49 of 51) of the patients had the required minimum follow-up and were included. Among the included patients, 88% (43 of 49) were available for a minimum follow-up of 24 months, whereas 12% (6) had < 24 months of follow-up but had complications earlier; thus, they were included for the analysis of complication-free survivorship. Seventy-eight percent (38) of patients were treated with a pelvic allograft combined with an acetabular cage, 16% (8) of patients received only a cemented cup, and 6% (3) of patients received a stemmed cementless cup. The mean ± SD follow-up time was 100 ± 77 months. The mean ± SD age at the time of reconstruction was 47 ± 17 years; 37% (18 of 49) of patients were female and 63% (31) were male. According to the Enneking and Dunham classification of pelvic resections, 39% (19) of patients had a Type I-II resection, 24% (12) had a Type II, 22% (11) had a Type II-III, 8% (4) had a Type I-II-III, 4% (2) had a Type I-II-IV, and 2% (1) had a Type I-II-III-IV. All patients had primary or secondary malignant or benign aggressive bone tumors: high-grade central chondrosarcoma (39% [19 of 49]), Ewing sarcoma (14% [7]), high-grade osteosarcoma (10% [5]), metastasis from carcinoma (10% [5]), dedifferentiated chondrosarcoma (10% [5]), peripheral low-grade chondrosarcoma (2% [1]), giant cell tumor of bone (2% [1]), osteoblastoma (2% [1]), hemangioendothelioma of bone (2% [1]), undifferentiated pleomorphic sarcoma of bone (2% [1]), malignant peripheral nerve sheath tumor of bone (2% [1]), radiation-induced sarcoma (2% [1]), or solitary plasmacytoma (2% [1]). The cumulative incidence of major complications, defined as surgical revision of any component of the reconstruction for mechanical complications and/or infections either surgically treated or not, and removal of the allograft as endpoints indicating failure, respectively, were estimated according to the competing-risk method. Complications were assessed through the revision of clinical charts. Death before the primary event of interest was considered a competing event. Comparisons of cumulative incidence curves across patient subgroups were performed with the Gray test. Normality of variables was assessed using the Shapiro-Wilk test, and heteroscedasticity was assessed using the Levene test. Accordingly, postoperative functional outcomes were compared across groups using a Welch t-test. Group means were reported in each plot. The relationship between functional score and length of follow-up was determined using a Pearson correlation coefficient. Significance was set at p < 0.05. The functional results were assessed using the MSTS score. The MSTS score was evaluated in patients with at least 2 years of follow-up in whom the pelvic allograft was retained at last clinical follow-up. Functional outcomes were assessed through the review of our institutional database. RESULTS: The cumulative incidence of major complications was 24% (95% confidence interval [CI] 13% to 37%) at 5 years and 33% (95% CI 20% to 46%) at 10 and 15 years. The mean ± SD MSTS score was 23 ± 5, assessed 10 ± 6 years after the procedure. The cumulative incidence of graft removal was 8% (95% CI 3% to 18%) at 5 and 10 years and 12% (95% CI 4% to 24%) at 15 years. CONCLUSION: Allograft-prosthesis composite may represent an effective reconstructive option after periacetabular resection for primary bone tumors even in the era of 3D-printed implants; it still could have a role in patients with long life expectancy who are treated for tumors that were not managed with chemotherapy or radiotherapy and in whom the iliac wing is fully or partially preserved. Larger studies comparing periacetabular allograft-prosthesis composite with other reconstructive options such as modular and custom-made endoprostheses, as well as recycled autograft-prosthesis composites, are warranted to assess the potential benefits of one technique over the other. LEVEL OF EVIDENCE: Level IV, therapeutic study.
引用
- Scanferla R, Rajan S, Scolari F, et al. Periacetabular Resection for Bone Tumors: Is There Still a Role for Massive Allograft-prosthesis Composite Reconstructions? Clin Orthop Relat Res. 2025. PMID: 41289179. doi:10.1097/CORR.0000000000003754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。